Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression

References

• American Psychiatric Association 2022. Diagnostic and statistical manual of mental disorders, Fifth Edition, Text Revision. Arlington, VA: American Psychiatric Association.
   Google Scholar
• Anderson P.O 2021. Antidepressants and Breastfeeding. Breastfeed Med. 16(1):5–7. doi:10.1089/bfm.2020.0350.
   PubMed Web of Science ®Google Scholar
• Balan I, Patterson R, Boero G, Krohn H, O'Buckley TK, Meltzer-Brody S, Morrow AL. 2023. Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways. EBioMedicine. 89:104473. doi: 10.1016/j.ebiom.2023.104473.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. 2017. Progress report on new antiepileptic drugs: a summary of the thirteenth eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 58(2):181–221. doi: 10.1111/epi.13634.
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. 2000. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 157(6):924–930. doi: 10.1176/appi.ajp.157.6.924.
   PubMed Web of Science ®Google Scholar
• Brii Biosciences Limited 2023a. A Study of BRII-297 in healthy adult subjects. National Library of Medicine (US); [accessed 2023 May 23]. https://clinicaltrials.gov/ct2/show/NCT05845840.
   Google Scholar
• Brii Biosciences Limited 2023b. Brii Biosciences announces top-line results from phase 1 study of BRII-296, A long-acting therapy in development for postpartum depression. PRNewswire; [updated 26 Sep 2022; accessed 2023 23 May]. https://www.prnewswire.com/news-releases/brii-biosciences-announces-top-line-results-from-phase-1-study-of-brii-296-a-long-acting-therapy-in-development-for-postpartum-depression-301632804.html.
   Google Scholar
• Brown JVE, Wilson CA, Ayre K, Robertson L, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. 2021. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev. 2(2):CD013560.
   PubMedGoogle Scholar
• Bullock A, Nandy I, Garcia M, Deligiannidis K, Wald J. 2022. An open-label study to evaluate concentrations of Zuranolone in the Breast Milk of Healthy Lactating Women. 9th World Congress on Women’s Mental Health; November 6–9, 2022; Maastricht, Netherlands [Scientific poster presentation at the world congress on women' mental health].
   Google Scholar
• Byatt N, Deligiannidis KM, Freeman MP. 2013. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 127(2):94–114. doi: 10.1111/acps.12042.
   PubMed Web of Science ®Google Scholar
• Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, Golani LK, Cook JM, Witkin JM. 2022. GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA(A) receptors. Pharmacol Ther. 234:108035. doi: 10.1016/j.pharmthera.2021.108035.
   PubMed Web of Science ®Google Scholar
• Chibanda D, Shetty AK, Tshimanga M, Woelk G, Stranix-Chibanda L, Rusakaniko S. 2014. Group problem-solving therapy for postnatal depression among HIV-positive and HIV-negative mothers in Zimbabwe. J Int Assoc Providers AIDS Care. 13(4):335–341. doi: 10.1177/2325957413495564.
   PubMedGoogle Scholar
• Cohen L, Viguera A, Bouffard S, Nonacs R, Morabito C, Collins M, Ablon J. 2001. Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry. 62(8):592–596. doi: 10.4088/jcp.v62n0803.
   PubMed Web of Science ®Google Scholar
• Cuijpers P, Brannmark JG, van Straten A. 2008. Psychological treatment of postpartum depression: a meta‐analysis. J Clin Psychol. 64(1):103–118. doi: 10.1002/jclp.20432.
   PubMed Web of Science ®Google Scholar
• De SK. 2023. Ganaxolone: first FDA-approved medicine for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Curr Med Chem. 31(4):388–392. doi: 10.2174/0929867330666230320123952.
   Web of Science ®Google Scholar
• Deligiannidis KM, Kroll-Desrosiers AR, Mo S, Nguyen HP, Svenson A, Jaitly N, Hall JE, Barton BA, Rothschild AJ, Shaffer SA. 2016. Peripartum neuroactive steroid and gamma-aminobutyric acid profiles in women at-risk for postpartum depression. Psychoneuroendocrinology. 70:98–107. doi: 10.1016/j.psyneuen.2016.05.010.
   PubMed Web of Science ®Google Scholar
• Deligiannidis KM, Kroll-Desrosiers AR, Tan Y, Dubuke ML, Shaffer SA. 2020. Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: a liquid chromatography-tandem mass spectrometry analysis. Psychoneuroendocrinology. 121:104827. doi: 10.1016/j.psyneuen.2020.104827.
   PubMed Web of Science ®Google Scholar
• Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, et al. 2021. Effect of Zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 78(9):951–959. doi: 10.1001/jamapsychiatry.2021.1559.
   PubMed Web of Science ®Google Scholar
• Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman MP, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, et al. 2023. Zuranolone for the treatment of adults with postpartum depression. Am J Psychiatry. 180(9):668–675. doi: 10.1176/appi.ajp.20220785.
   PubMed Web of Science ®Google Scholar
• Dennis C, Ross L, Herxheimer A. 2008. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev. 2008(4):CD001690. doi:10.1002/14651858.CD001690.pub2.
   PubMedGoogle Scholar
• Drugs and Lactation Database (LactMed®) 2006. National Institute of Child Health and Human Development.
   Google Scholar
• Eberhard-Gran M, Eskild A, Opjordsmoen S. 2006. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs. 20(3):187–198. doi: 10.2165/00023210-200620030-00002.
   PubMed Web of Science ®Google Scholar
• Epperson CN, Rubinow DR, Meltzer-Brody S, Deligiannidis KM, Riesenberg R, Krystal AD, Bankole K, Huang MY, Li H, Brown C, et al. 2023. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord. 320:353–359. doi: 10.1016/j.jad.2022.09.143.
   PubMed Web of Science ®Google Scholar
• Figueiredo F, Parada A, de Araujo L, Silva W, Del-Ben C. 2015. The influence of genetic factors on peripartum depression: a systematic review. J Affect Disord. 172:265–273. doi: 10.1016/j.jad.2014.10.016.
   PubMed Web of Science ®Google Scholar
• Flynn S, Shaw J, Abel K. 2013. Filicide: mental illness in those who kill their children. PLOS One. 8(4):e58981. doi: 10.1371/journal.pone.0058981.
   PubMed Web of Science ®Google Scholar
• Galea LA, Wide JK, Barr AM. 2001. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. Behav Brain Res. 122(1):1–9. doi: 10.1016/s0166-4328(01)00170-x.
   PubMed Web of Science ®Google Scholar
• Garafola S, Shiferaw E, Dev V. 2023. Safety of brexanolone in adults with postpartum depression: postmarketing surveillance data. Drugs Real World Outcomes. 10(3):351–356. doi: 10.1007/s40801-023-00372-4.
   PubMedGoogle Scholar
• Gerbera Therapeutics Inc 2023. Nora 520. https://www.gerberarx.com/en/product/detail/NORA520. [accessed 2023 May 23].
   Google Scholar
• Gregoire A, Kumar R, Everitt B, Henderson A, Studd J. 1996. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 347(9006):930–933. doi: 10.1016/s0140-6736(96)91414-2.
   PubMed Web of Science ®Google Scholar
• Hecking J, Davoudian PA, Wilkinson ST. 2021. Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. Chronic Stress . 5:24705470211020446. doi: 10.1177/24705470211020446.
   Google Scholar
• Hellgren C, Akerud H, Skalkidou A, Backstrom T, Sundstrom-Poromaa I. 2014. Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. Neuropsychobiology. 69(3):147–153. doi: 10.1159/000358838.
   PubMed Web of Science ®Google Scholar
• Hellgren C, Comasco E, Skalkidou A, Sundstrom-Poromaa I. 2017. Allopregnanolone levels and depressive symptoms during pregnancy in relation to single nucleotide polymorphisms in the allopregnanolone synthesis pathway. Horm Behav. 94:106–113. doi: 10.1016/j.yhbeh.2017.06.008.
   PubMed Web of Science ®Google Scholar
• Hendrick V, Altshuler LL, Suri R. 1998. Hormonal changes in the postpartum and implications for postpartum depression. Psychosomatics. 39(2):93–101. doi: 10.1016/S0033-3182(98)71355-6.
   PubMed Web of Science ®Google Scholar
• Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, et al. 2017. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 390(10093):480–489. doi: 10.1016/S0140-6736(17)31264-3.
   PubMed Web of Science ®Google Scholar
• Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, Meltzer-Brody S. 2017. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol Clin Exp. 32:e2576. https://doi.org/10.1002/hug.2576.
   PubMed Web of Science ®Google Scholar
• Kettunen P, Koistinen E, Hintikka J, Perheentupa A. 2022. Oestrogen therapy for postpartum depression: efficacy and adverse effects. A double-blind, randomized, placebo-controlled pilot study. Nord J Psychiatry. 76(5):348–357. doi: 10.1080/08039488.2021.1974556.
   PubMed Web of Science ®Google Scholar
• Knight M, Bunch K, Tuffnell D, Patel R, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk J. 2021. Saving Lives, Improving Mothers’ Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2017-19. Oxford: National Perinatal Epidemiology Unit, University of Oxford.
   Google Scholar
• Lawrie T, Hofmeyr G, De Jager M, Berk M, Paiker J, Viljoen E. 1998. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 105(10):1082–1090. doi: 10.1111/j.1471-0528.1998.tb09940.x.
   PubMedGoogle Scholar
• Li H, Martinez P, Li X, Schenkel L, Nieman L, Rubinow D, Schmidt P. 2020. Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study. Arch Womens Ment Health. 23(3):401–412. doi: 10.1007/s00737-019-00991-3.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang S, Wang G. 2022. Prevalence and risk factors of postpartum depression in women: a systematic review and meta-analysis. J Clin Nurs. 31(19-–20):2665–2677. doi: 10.1111/jocn.16121.
   PubMed Web of Science ®Google Scholar
• Maguire J, McCormack C, Mitchell A, Monk C. 2020. Neurobiology of maternal mental illness. Handb Clin Neurol. 171:97–116.–
   PubMedGoogle Scholar
• Maguire J, Mody I. 2008. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 59(2):207–213. doi: 10.1016/j.neuron.2008.06.019.
   PubMed Web of Science ®Google Scholar
• Maguire J, Mody I. 2009. Steroid hormone fluctuations and GABA(A)R plasticity. Psychoneuroendocrinology. 34 (Suppl 1):S84–S90. doi: 10.1016/j.psyneuen.2009.06.019.
   PubMedGoogle Scholar
• Marinus Pharmaceuticals 2019. Marinus pharmaceuticals announces data from Magnolia and Amaryllis Phase 2 studies in women with postpartum depression. [accessed 2023 May 23]. https://www.globenewswire.com/news-release/2019/07/23/1886335/0/en/Marinus-Pharmaceuticals-Announces-Data-from-Magnolia-and-Amaryllis-Phase-2-Studies-in-Women-with-Postpartum-Depression.html.
   Google Scholar
• Marinus Pharmaceuticals 2023a. A clinical trial of intravenous (IV) ganaxolone in women with postpartum depression. National Library of Medicine (S); [updated Feb 8; accessed 2023 1 June]. https://clinicaltrials.gov/study/NCT03228394.
   Google Scholar
• Marinus Pharmaceuticals 2023b. A clinical trial of oral ganaxolone in women with postpartum depression. National Library of Medicine (US); [updated 30 Jan 2023; accessed 2023 1 June]. https://clinicaltrials.gov/study/NCT03460756.
   Google Scholar
• Martinez Botella G, Salituro FG, Harrison BL, Beresis RT, Bai Z, Blanco MJ, Belfort GM, Dai J, Loya CM, Ackley MA, et al. 2017. Neuroactive steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (γ-Aminobutyric Acid)(A) receptor. J Med Chem. 60(18):7810–7819. doi: 10.1021/acs.jmedchem.7b00846.
   PubMed Web of Science ®Google Scholar
• McEvoy K, Payne J, Osborne L. 2018. Neuroactive steroids and perinatal depression: a review of recent literature. Curr Psychiatry Rep. 20(9):78. doi: 10.1007/s11920-018-0937-4.
   PubMed Web of Science ®Google Scholar
• Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, et al. 2018. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 392(10152):1058–1070. doi: 10.1016/S0140-6736(18)31551-4.
   PubMed Web of Science ®Google Scholar
• Misri S, Swift E, Abizadeh J, Shankar R. 2016. Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing. Ther Adv Psychopharmacol. 6(4):269–276. doi: 10.1177/2045125316656297.
   PubMed Web of Science ®Google Scholar
• Nonacs R, Soares C, Viguera A, Pearson K, Poitras J, Cohen L. 2005. Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmacol. 8(3):445–449. doi: 10.1017/S1461145705005079.
   PubMed Web of Science ®Google Scholar
• Osborne LM, Betz JF, Yenokyan G, Standeven LR, Payne JL. 2019. The role of allopregnanolone in pregnancy in predicting postpartum anxiety symptoms. Front Psychol. 10:1033. doi: 10.3389/fpsyg.2019.01033.
   PubMed Web of Science ®Google Scholar
• Osborne LM, Gispen F, Sanyal A, Yenokyan G, Meilman S, Payne JL. 2017. Lower allopregnanolone during pregnancy predicts postpartum depression: an exploratory study. Psychoneuroendocrinology. 79:116–121. doi: 10.1016/j.psyneuen.2017.02.012.
   PubMed Web of Science ®Google Scholar
• Patterson R, Krohn H, Richardson E, Kimmel M, Meltzer-Brody S. 2022. A brexanolone treatment program at an academic medical center: patient selection, 90-day posttreatment outcomes, and lessons learned. J Acad Consult Liaison Psychiatry. 63(1):14–22. doi: 10.1016/j.jaclp.2021.08.001.
   PubMedGoogle Scholar
• Payne JL, Maguire J. 2019. Pathophysiological mechanisms implicated in postpartum depression. Front Neuroendocrinol. 52:165–180. doi: 10.1016/j.yfrne.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Pieh Holder K. 2015. Contraception and breastfeeding. Clin Obstet Gynecol. 58(4):928–935. doi: 10.1097/GRF.0000000000000157.
   PubMed Web of Science ®Google Scholar
• Sage Therapeutics 2023. A study to assess the safe-use conditions for administration of ZULRESSO® in a home setting. National Library of medicine (US); [accessed 2023 June 1]. https://clinicaltrials.gov/ct2/show/NCT05059600.
   Google Scholar
• Santoro N, Liss J. 2021. Compounded bioidentical hormones: myths and realities. Clin Obstet Gynecol. 64(4):793–802. doi: 10.1097/GRF.0000000000000650.
   PubMed Web of Science ®Google Scholar
• Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso H, Idahl A, Lehtinen M, Surcel HM, Fortner RT. 2016. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 16(1):146. doi: 10.1186/s12884-016-0937-5.
   PubMedGoogle Scholar
• Singata-Madliki M, Hofmeyr G, Lawrie T. 2016. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care. 42(3):171–176. doi: 10.1136/jfprhc-2015-101334.
   PubMedGoogle Scholar
• Slomian J, Honvo G, Emonts P, Reginster J, Bruyère O. 2019. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health. 15:1745506519844044. doi: 10.1177/1745506519844044.
   Web of Science ®Google Scholar
• Stefaniak M, Dmoch-Gajzlerska E, Jankowska K, Rogowski A, Kajdy A, Maksym R. 2023. Progesterone and its metabolites play a beneficial role in affect regulation in the female brain. Pharmaceuticals. 16(4):520. doi: 10.3390/ph16040520.
   Web of Science ®Google Scholar
• Suri R, Burt V, Altshuler L. 2005. Nefazodone for the treatment of postpartum depression. Arch Womens Ment Health. 8(1):55–56. doi: 10.1007/s00737-005-0071-2.
   PubMed Web of Science ®Google Scholar
• mTrost S, Beauregard J, Chandra G, Njie F, Berry J, Harvey A, Goodman D. 2022. Pregnancy-related deaths: data from maternal mortality review committees in 36 US States, 2017–2019. Atlanta, GA: Centers for Disease Control and Prevention US Department of Health and Human Services.
   Google Scholar
• Wald J, Henningsson A, Hanze E, Hoffmann E, Li H, Colquhoun H, Deligiannidis KM. 2022. Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose. Clin Pharmacokinet. 61(9):1307–1319. doi: 10.1007/s40262-022-01155-w.
   PubMed Web of Science ®Google Scholar
• Wisner K, Hanusa B, Perel J, Peindl K, Piontek C, Sit D, Findling R, Moses-Kolko E. 2006. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 26(4):353–360. doi: 10.1097/01.jcp.0000227706.56870.dd.
   PubMed Web of Science ®Google Scholar
• Wisner K, Sit D, Moses-Kolko E, Driscoll K, Prairie B, Stika C, Eng H, Dills J, Luther J, Wisniewski S. 2015. Transdermal estradiol treatment for postpartum depression: a pilot, randomized trial. J Clin Psychopharmacol. 35(4):389–395. doi: 10.1097/JCP.0000000000000351.
   PubMed Web of Science ®Google Scholar
• Wisner KL, Moses-Kolko EL, Sit DKY. 2010. Postpartum depression: a disorder in search of a definition [Letter]. Arch Womens Ment Health. 13(1):37–40. doi: 10.1007/s00737-009-0119-9.
   PubMed Web of Science ®Google Scholar
• ZULRESSO Prescribing Information 2022. Cambridge, MA: Sage Therapeutics, Inc.
   Google Scholar
• ZURZUVAE Prescribing Information 2023. Cambridge, MA: Biogen, Inc. and Sage Therapeutics, Inc.
   Google Scholar